Lisocabtagene maraleucel

Overview

Lisocabtagene maraleucel is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, representing a groundbreaking form of personalized immunotherapy.

• Generic Name: Lisocabtagene maraleucel
• US Brand Name: Breyanzi®
• Drug Class: Cellular Immunotherapy, Gene-Modified Autologous T-Cell Immunotherapy
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Approved for specific oncological indications.

Mechanism of Action

Lisocabtagene maraleucel is an adoptive cell therapy that genetically reprograms a patient’s own T cells to target and eliminate cancer cells expressing CD19.

• Molecular Target: The therapy targets the CD19 antigen, a cell surface protein expressed on malignant and normal B cells.
• Cellular Impact: A patient’s T cells are collected via leukapheresis and genetically engineered ex vivo to express a CAR. This CAR consists of an anti-CD19 single-chain variable fragment (scFv) linked to intracellular T-cell signaling domains (4-1BB and CD3-zeta).
• Result: Once reinfused, these engineered CAR T cells recognize and bind to CD19-expressing cells. This binding activates the T cells, leading to:
  1. Proliferation: Rapid expansion of the CAR T-cell population in vivo.
  2. Cytotoxicity: Direct killing of the bound CD19+ target cells through the release of perforin and granzymes.
  3. Cytokine Release: Inflammatory signaling that further recruits and activates the immune system.
• This results in a potent, targeted immune response against CD19-positive B-cell malignancies.

FDA-Approved Clinical Indications

Lisocabtagene maraleucel is FDA-approved for specific, advanced B-cell malignancies.

Oncological Indications (Marketed as Breyanzi®):

• Large B-cell Lymphoma (LBCL): Treatment of adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

Non-Oncological Indications:

• There are currently no FDA-approved non-oncological uses for lisocabtagene maraleucel.

Dosage and Administration Protocols

Lisocabtagene maraleucel is a one-time intravenous infusion of genetically modified autologous T cells. Treatment must be administered at a certified healthcare facility.

Standard Treatment Dosage:

• The target dose is based on the number of chimeric antigen receptor (CAR)-positive viable T cells and the patient’s body weight.
• Lymphodepleting Chemotherapy: Fludarabine (30 mg/m²/day) and cyclophosphamide (300 mg/m²/day) must be administered for 3 days beginning 5 to 7 days before infusion.
• Infusion Time: The lisocabtagene maraleucel infusion is administered over 30 to 60 minutes.

Dosing Guidelines:

Dose is calculated based on patient weight. No dose adjustments are made for renal or hepatic impairment.

Clinical Efficacy and Research Outcomes

Pivotal clinical trials have demonstrated high response rates in heavily pre-treated patients with aggressive lymphoma.

• Efficacy in LBCL: In the pivotal TRANSCEND NHL 001 trial, lisocabtagene maraleucel showed a best objective response rate (ORR) of 73% and a complete response (CR) rate of 53% in refractory/relapsed LBCL. With a median follow-up of 18.8 months, the median duration of response was 16.7 months for all responders. Real-world evidence (2020-2025) corroborates these efficacy outcomes outside clinical trials.
• Comparative Data: In the second-line setting for primary refractory or early-relapsing LBCL, the TRANSFORM trial demonstrated superior efficacy of lisocabtagene maraleucel compared to standard salvage chemotherapy followed by autologous stem cell transplant (ASCT). CAR T-cell therapy resulted in significantly improved event-free survival (EFS) and complete response rates.
• Long-term Follow-up: Ongoing studies show a plateau in survival curves, suggesting a potential for durable, long-term remission in a subset of patients who achieve a complete response.

Safety Profile and Side Effects

Black Box Warnings:

1. Cytokine Release Syndrome (CRS): Potentially life-threatening systemic inflammatory response.
2. Neurologic Toxicities: Including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which can be fatal or life-threatening.

Common Side Effects (>10%):

• Hematologic: Prolonged cytopenias (neutropenia, anemia, thrombocytopenia), infections.
• Constitutional: Fatigue, fever, chills, hypotension, tachycardia.
• Gastrointestinal: Nausea, diarrhea, decreased appetite.
• Neurologic: Headache, dizziness, tremor, encephalopathy.
• Musculoskeletal: Musculoskeletal pain.

Serious Adverse Events & Management:

1. Cytokine Release Syndrome (CRS): Manifests with fever, hypoxia, and hypotension. Managed with supportive care (IV fluids, oxygen, vasopressors) and tocilizumab (IL-6 receptor antagonist) +/- corticosteroids.
2. Neurologic Toxicities/ICANS: Symptoms include aphasia, altered consciousness, and seizures. Managed with corticosteroids (e.g., dexamethasone). Prophylactic use of anti-seizure medication may be considered.
3. Prolonged Cytopenias: May require growth factor support (e.g., G-CSF) and infection prophylaxis.
4. Hypogammaglobulinemia: Common due to B-cell aplasia; may require intravenous immunoglobulin (IVIG) replacement.

Connection to Stem Cell & Regenerative Medicine

Lisocabtagene maraleucel is a paradigm of regenerative and cellular medicine, where a patient’s own cells are engineered to become a living drug.

• Autologous Cellular Therapy: This treatment exemplifies ex vivo cell manipulation and reinfusion, a core concept in regenerative medicine. The process of leukapheresis, genetic modification, expansion, and reinfusion represents a highly personalized therapeutic platform.
• Combination Strategies: Current research is exploring the combination of CAR T-cell therapies like lisocabtagene maraleucel with other immunomodulators, checkpoint inhibitors, or targeted small molecules to enhance efficacy, persistence of CAR T cells, and overcome resistance mechanisms in the tumor microenvironment.
• Next-Generation Engineering: Ongoing research focuses on “armoring” CAR T cells (e.g., with cytokine secretion or resistance to immunosuppression) and developing allogeneic (“off-the-shelf”) CAR T-cell products from healthy donors to reduce manufacturing time and variability.

Patient Management and Practical Recommendations

Pre-Treatment

• Eligibility & Counseling: Comprehensive evaluation for fitness, including cardiac, pulmonary, and renal function. Patients must be informed of the risks of CRS and neurotoxicity and agree to stay near the treatment center for at least 4 weeks post-infusion.
• Tumor Assessment: Confirm CD19 positivity of the malignancy via biopsy.
• Infectious Disease Screening: Screen for HIV, HBV, HCV, and other relevant infections.
• Central Line: Ensure placement of a dedicated central venous catheter.

During & Post-Treatment

• Administration Site: Administer only at a certified healthcare facility equipped to manage severe CRS and neurologic toxicities.
• Monitoring: Patients require daily monitoring for signs of CRS and neurotoxicity for at least 7 days post-infusion. Hospitalization for a minimum of 7 days is standard. Monitor blood counts and immunoglobulin levels regularly for weeks to months.
• Prophylaxis: Provide prophylaxis for tumor lysis syndrome, infections, and seizures as per protocol.

Do’s and Don’ts

• DO: Report fever, chills, dizziness, confusion, or shortness of breath immediately after infusion.
• DO: Arrange for a dedicated caregiver and avoid driving or operating heavy machinery for at least 8 weeks post-infusion.
• DON’T: Administer live vaccines during or after treatment.
• DON’T: Use corticosteroids or other immunosuppressants prior to infusion unless for lymphodepleting chemotherapy or management of life-threatening adverse reactions.

Legal Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. This therapy involves complex, potentially severe risks and is only administered within specific certified clinical settings. All treatment decisions must be made in consultation with a qualified oncologist specializing in cellular immunotherapy.